SLCO1B1 rs4149014: Understanding Statin Transport and Response
The rs4149014 variant is a genetic change located within the SLCO1B1 gene, which provides instructions for making a protein that transports substances into the liver. This variant is primarily studied in the context of pharmacogenomics, specifically regarding how the body processes certain statin medications used to manage cholesterol.
What each genotype means
Normal transporter activity
This genotype is considered the reference or normal activity profile for the SLCO1B1 gene. Individuals with this profile typically have standard hepatic uptake of statin medications, which is associated with a lower risk of statin-induced muscle symptoms compared to those carrying the C allele. Please discuss your medication regimen and any muscle-related concerns with your clinician or pharmacist.
This is the most common genotype in most global populations, though frequencies vary significantly by ancestry.
Reduced transporter activity
This genotype, often associated with the *5 or *15 star allele haplotypes, is linked to reduced function of the OATP1B1 transporter protein. This may lead to higher levels of certain statins in your blood, which is statistically associated with an increased risk of muscle pain or myopathy. Please consult your healthcare provider or pharmacist to discuss whether this information should influence your choice or dosage of statin therapy.
Carried by a significant portion of the population, with the C allele frequency typically ranging from 10% to 20% in European and East Asian populations.
Significantly reduced transporter activity
This genotype is associated with the lowest level of OATP1B1 transporter activity for this variant, which can lead to higher systemic exposure to statin medications. Research indicates a substantially higher statistical risk of developing statin-induced muscle symptoms compared to individuals with the TT genotype. It is important to discuss this genetic finding with your doctor or pharmacist to ensure your medication plan is appropriate for your profile.
This is the least common of the three genotypes, occurring in a smaller percentage of the population globally.
What is the rs4149014 Variant?
The rs4149014 variant is a single nucleotide polymorphism (SNP) found within the SLCO1B1 gene. In genetics, a SNP represents a variation at a single position in the DNA sequence. This specific variant is often discussed alongside other functional markers in the same gene, such as rs4149056, which is well-documented for its role in altering the function of the OATP1B1 transporter protein. While rs4149014 is located in a region that influences the gene's activity, it is important to note that genetic variants do not act in isolation. They are part of a complex biological system where multiple factors, including other genes, environmental influences, and lifestyle choices, contribute to how an individual responds to medications. Understanding this variant requires looking at its position within the gene and how that position relates to the overall production and efficiency of the transporter protein it encodes.
The Role of the SLCO1B1 Gene
The SLCO1B1 gene encodes the organic anion transporting polypeptide 1B1 (OATP1B1). This protein acts as a gatekeeper in the liver, facilitating the uptake of various compounds from the blood into liver cells (hepatocytes). This process is essential for the body's detoxification and clearance mechanisms. OATP1B1 is responsible for transporting a wide range of substances, including bilirubin, bile acids, and several types of medications, such as statins. By moving these substances into the liver, the protein allows the body to process and eventually eliminate them. When the SLCO1B1 gene contains variants that alter the structure or expression of this protein, the efficiency of this transport process can be affected. This can lead to changes in the concentration of these substances in the bloodstream, which is why researchers study this gene closely in the field of pharmacogenomics.
Research and Clinical Evidence
Research into SLCO1B1 variants has largely focused on their association with statin-induced muscle symptoms, often referred to as statin-associated muscle symptoms (SAMS). Studies have shown that certain variants in this gene can lead to reduced transporter function, potentially increasing the levels of statins in the blood and thereby increasing the risk of side effects. However, the evidence for rs4149014 specifically is considered limited compared to other, more extensively studied markers in the same gene. While some studies suggest associations with altered transport activity, clinical evidence linking this specific variant to clear-cut outcomes remains mixed. It is crucial to understand that having a particular genotype does not guarantee a specific clinical outcome. The field of pharmacogenomics is still evolving, and current guidelines often emphasize that genetic testing should be interpreted by qualified healthcare professionals who can consider the full clinical picture.
What You Can Do With This Information
If you have information about your SLCO1B1 genotype, it is important to view it as one piece of a much larger puzzle. You cannot use this information to diagnose yourself or to make independent decisions about your medication regimen. If you are concerned about how your body might respond to a statin or if you are experiencing side effects, the most important step is to consult your physician or pharmacist. They are equipped to evaluate your genetic information in the context of your medical history, current medications, and overall health goals. Never stop or change your prescribed medication dosage based on genetic test results without professional guidance. Genetic data can be a helpful tool for clinicians to personalize care, but it is not a substitute for clinical judgment and regular medical monitoring.
How common is this variant?
The rs4149014 variant is common globally, with a minor allele frequency typically ranging between 0.10 and 0.15, though this can vary significantly depending on ancestral background.
Frequently asked questions
Does having the rs4149014 variant mean I will have side effects from statins?
No, having a specific genotype does not guarantee that you will experience side effects. Many people with various genotypes take statins without issues, and side effects can be caused by many factors beyond genetics.
Should I get a genetic test for SLCO1B1 before starting a statin?
Routine genetic testing for SLCO1B1 is not currently standard practice for all patients starting statins. You should discuss the necessity of such testing with your doctor based on your specific health profile.
Is rs4149014 the same as the well-known SLCO1B1 521T>C variant?
No, rs4149014 is a distinct variant. While it is in the same gene, the variant most commonly cited in clinical pharmacogenomics literature regarding statin myopathy is rs4149056 (c.521T>C).
Can I change my SLCO1B1 genotype through diet or lifestyle?
No, your genotype is determined by the DNA you inherited from your parents and cannot be changed. However, lifestyle factors like diet and exercise remain fundamental to managing cholesterol levels regardless of your genetics.
Sources & further reading
Educational information only, last refreshed 9/17/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs4149014?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SLCO1B1
This missense variant (p.Pro155Thr) is associated with reduced OATP1B1 transporter function, which can lead to increased plasma concentrations of certain statins and higher risk of myopathy.
A regulatory variant in the SLCO1B1 gene influencing statin pharmacokinetics.
Defines the c.388A>G (p.Asn130Asp) variant, which is a component of the SLCO1B1*1B and *15 haplotypes, influencing hepatic statin uptake.
Non-synonymous coding polymorphism (p.Asn130Asp) defining the SLCO1B1*30 allele with modest alteration in hepatic statin uptake.
This variant (c.521T>C) is strongly associated with decreased function of the OATP1B1 transporter, significantly increasing the risk of statin-induced myopathy.
Known as SLCO1B1*1b (p.Asn130Asp), this variant alters hepatic transporter activity and modulates statin exposure and pharmacokinetic clearance.